John E. Imhoff - Mar 6, 2025 Form 4 Insider Report for GUIDED THERAPEUTICS INC (GTHP)

Role
Director, 10%+ Owner
Signature
/s/ John E. Imhoff
Stock symbol
GTHP
Transactions as of
Mar 6, 2025
Transactions value $
$2,813,007
Form type
4
Date filed
4/17/2025, 04:06 PM
Previous filing
Feb 18, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHP Preferred Series D Stock Other -300 -100% 0 Mar 6, 2025 Direct F1
transaction GTHP Common Stock Other +900K +10.27% 9.66M Mar 6, 2025 Direct F1
transaction GTHP Preferred Series C2 Stock Other -2.4K -100% 0 Mar 6, 2025 Direct F2
transaction GTHP Common Stock Other $2.4M +4.8M +49.69% $0.50 14.5M Mar 6, 2025 Direct F2
transaction GTHP Preferred Series C Stock Purchase +286 286 Mar 7, 2025 Direct F3
transaction GTHP Preferred Series C Stock Other -286 -100% 0 Mar 11, 2025 Direct F3
transaction GTHP Common Stock Other $286K +2.26M +15.62% $0.13 16.7M Mar 11, 2025 Direct F3
transaction GTHP Common Stock Purchase $100K +1M +5.98% $0.10 17.7M Mar 18, 2025 Direct F4
transaction GTHP Common Stock Purchase $26.3K +263K +1.48% $0.10 18M Mar 18, 2025 Direct F5
transaction GTHP Common Stock Other +6.37K +0.04% 18M Apr 10, 2025 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHP Warrants Purchase +1M 1M Mar 18, 2025 Common Stock 1M $0.13 Direct F4
transaction GTHP Warrants Purchase +263K +26.31% 1.26M Mar 18, 2025 Common Stock 263K $0.13 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price.
F2 On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares.
F3 On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares.
F4 On March 18, 2025, the Company entered into a Securities Purchase Agreement (the "March Purchase Agreement") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the "March Warrants"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share.
F5 In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above.
F6 These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943.